ACAAI: Considerable delay seen from Rx to approval for children's biologics
There is a considerable delay from prescription of biologic therapy to final approval for pediatric patients, and almost 40% of prescriptions requiring a prior authorization (PA) are denied, according to a study presented at the annual meeting of the American College of Allergy, Asthma and Immunology, held from Nov. 12 to 16 in Phoenix.
Read original article on Medical Xpress - latest medical and health news stories →